Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12745880 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL17680204 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL16980588 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL19129781 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL16079839 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL25495867 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL8324123 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL16883362 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL19728869 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 | |
| SCHEMBL13170766 | 0.88 | GLB1 (0.34) | GLB1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021338-A1 | FLUOROCYCLOPENTENYLCYTOSINE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021338-A1 | FLUOROCYCLOPENTENYLCYTOSINE METHODS OF USE | TYMP, DPYD, NUDT1 | GLB1 1183/4885CA2 2475/4885CA1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.